Astellas' Vyloy Zolbetuximab Approved for Gastric Cancer Treatment

UK Approves New Targeted Cancer Treatment

Astellas Pharma's (OTCPKALPMF) Vyloy (zolbetuximab) has been approved by the UK's Medicines and Healthcare products regulatory agency (MHRA) for use in combination with standard chemotherapy for adults with locally advanced unresectable or metastatic gastric or gastro-esophageal junction adenocarcinoma.

European Medicines Agency Accepts Marketing Authorization Application

The European Medicines Agency (EMA) has accepted Astellas' Marketing Authorization Application for zolbetuximab, which targets patients with HER2-positive gastric cancer.

Worldwide Approvals

In addition to the UK, Vyloy has also been approved in Japan for the treatment of gastric cancer. The drug is currently under review by regulatory authorities in other countries.